OPT101

DRUG4 trials

Sponsors

Op-T LLC

Conditions

Community Acquired Pneumonia (CAP)Diabetes Mellitus, Type 1HealthySepsisType I Diabetes

Phase 1

1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.

CompletedNCT04589403

Op-T LLCHealthy

Start: 2021-02-18End: 2021-09-27Updated: 2025-09-15

OPT101 in Type 1 Diabetes Patients

CompletedNCT05428943

Op-T LLCDiabetes Mellitus, Type 1

Start: 2022-09-27End: 2024-02-21Updated: 2026-08-10

OPT101 in Patients With Community Acquired Pneumonia (CAP) With Sepsis

Not yet recruitingNCT06669403

Op-T LLCCommunity Acquired Pneumonia (CAP), Sepsis

Start: 2025-12-31End: 2026-05-31Target: 26Updated: 2025-09-15

Phase 2

Pharmacokinetic and Early Efficacy of OPT101 in Patients With Type 1 Diabetes Mellitus

RecruitingNCT06964087

Op-T LLCType I Diabetes

Start: 2026-04-10End: 2028-08-19Target: 72Updated: 2026-04-06